Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide vs Methotrexate in Difficult-to-Treat Cutaneous Lupus Erythematosus
NCT06965244Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lenalidomide in cutaneous lupus erythematosus (CLE), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT06965244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965244.